David Dankort’s lab’s latest paper in @MCR_AACR identifies the Hippo pathway inhibitor MOB3A as a novel suppressor of RAS and BRAF oncogene-induced senescence. Re-engagement of the Hippo pathway by MOB3A targeting could prove effective in the context of Ras-driven tumours.